Affiliation:
1. Department of Applied Science and Humanities, Sahrdaya College of Engineering and Technology, Affiliated to APJ Abdul Kalam
Technological University, Kodakara, Thrissur, Kerala, India
2. Department of Biotechnology, Sahrdaya College of Engineering and
Technology, Affiliated to APJ Abdul Kalam Technological University, Kodakara, Thrissur, Kerala, India
Abstract
Background:
Colorectal cancer (CRC) is considered the second deadliest cancer in the world. One
of the reasons for the occurrence of this cancer is the deregulation of the Epidermal Growth Factor Receptor
(EGFR), which plays a critical role in regulating cell division, persistence, differentiation, and migration. The
overexpression of the EGFR protein leads to its dysregulation and causes CRC.
Objective:
Hence, this work aims to identify and validate novel EGFR inhibitors for the treatment of colorectal
cancer employing various computer aided techniques such as pharmacophore modeling, docking, molecular
dynamic simulation and Quantitative Structure-Activity Relationship (QSAR) analysis.
Methods:
In this work, a shared-featured ligand-based pharmacophore model was generated using the known
inhibitors of EGFR. The best model was validated and screened against ZincPharmer and Maybridge databases,
and 143 hits were obtained. Pharmacokinetic and toxicological properties of these hits were studied, and the
acceptable ligands were docked against EGFR. The best five protein-ligand complexes with binding energy less
than -5 kcal/mol were selected. The molecular dynamic simulation studies of these complexes were conducted
for 100 nanoseconds (ns), and the results were analyzed. The biological activity of this ligand was calculated
using QSAR analysis.
Results:
The best complex with Root Mean Square Deviation (RMSD) 3.429 Å and Radius of Gyration (RoG)
20.181 Å was selected. The Root Mean Square Fluctuations (RMSF) results were also found to be satisfactory.
The biological activity of this ligand was found to be 1.38 μM.
Conclusion:
This work hereby proposes the ligand 2-((1,6-dimethyl-4-oxo-1,4-dihydropyridin-3-yl)oxy)-N-
(1H-indol-4-yl)acetamide as a potential EGFR inhibitor for the treatment of colorectal cancer. The wet lab
analysis must be conducted, however, to confirm this hypothesis.
Publisher
Bentham Science Publishers Ltd.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献